Nat Commun: BCL-XL直接调节RAS有利于癌细胞获得干细胞属性

2017-11-02 MedSci MedSci原创

肿瘤组织中,表达高水平抗凋亡蛋白(例如BCL-XL)的化学抗性细胞的积累被认为是在进展和/或初始治疗期间对敏感的低表达克隆进行反选择的结果。本研究中,研究人员发现,即使在没有促凋亡压力的情况下,BCL-XL表达选择性地有利于癌细胞群体。在转化的人乳腺上皮细胞中,BCL-XL有利于组合型活性RAS的下游信号的完全激活,以BH4依赖性的方式相互作用。对比蛋白质组学分析和功能测定表明,这对RAS诱导的干

肿瘤组织中,表达高水平抗凋亡蛋白(例如BCL-XL)的化学抗性细胞的积累被认为是在进展和/或初始治疗期间对敏感的低表达克隆进行反选择的结果。

本研究中,研究人员发现,即使在没有促凋亡压力的情况下,BCL-XL表达选择性地有利于癌细胞群体。在转化的人乳腺上皮细胞中,BCL-XL有利于组合型活性RAS的下游信号的完全激活,以BH4依赖性的方式相互作用。对比蛋白质组学分析和功能测定表明,这对RAS诱导的干细胞调节物的表达和维持癌症起始细胞(CIC)表型至关重要。

因此,耐药性癌细胞来自于RAS诱导的自我更新的BCL-XL调节驱动的阳性选择,其中凋亡耐药不一定是直接选择的特征。

原始出处:


Sophie de Carné Trécesson, Frédérique Souazé, et al., BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017; 8: 1123. Published online 2017 Oct 24. doi: 10.1038/s41467-017-01079-1

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882596, encodeId=e4791882596cf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 25 23:14:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087185, encodeId=f18a208e1853b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Jul 28 09:14:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252396, encodeId=59d5125239625, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593958, encodeId=6d91159395878, content=<a href='/topic/show?id=03d9326563' target=_blank style='color:#2F92EE;'>#Bcl-xL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3265, encryptionId=03d9326563, topicName=Bcl-xL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e08c18195851, createdName=yykkxiaodou, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2018-07-25 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882596, encodeId=e4791882596cf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 25 23:14:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087185, encodeId=f18a208e1853b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Jul 28 09:14:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252396, encodeId=59d5125239625, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593958, encodeId=6d91159395878, content=<a href='/topic/show?id=03d9326563' target=_blank style='color:#2F92EE;'>#Bcl-xL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3265, encryptionId=03d9326563, topicName=Bcl-xL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e08c18195851, createdName=yykkxiaodou, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2018-07-28 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882596, encodeId=e4791882596cf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 25 23:14:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087185, encodeId=f18a208e1853b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Jul 28 09:14:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252396, encodeId=59d5125239625, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593958, encodeId=6d91159395878, content=<a href='/topic/show?id=03d9326563' target=_blank style='color:#2F92EE;'>#Bcl-xL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3265, encryptionId=03d9326563, topicName=Bcl-xL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e08c18195851, createdName=yykkxiaodou, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882596, encodeId=e4791882596cf, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 25 23:14:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087185, encodeId=f18a208e1853b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Jul 28 09:14:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252396, encodeId=59d5125239625, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593958, encodeId=6d91159395878, content=<a href='/topic/show?id=03d9326563' target=_blank style='color:#2F92EE;'>#Bcl-xL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3265, encryptionId=03d9326563, topicName=Bcl-xL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e08c18195851, createdName=yykkxiaodou, createdTime=Sat Nov 04 06:14:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]

相关威廉亚洲官网

Nature Chem Bio:针对BCL-XL的高效小分子抑制剂WEHI-539被发现

日前,澳大利亚和美国Genentech公司的科学家合作,成功开发出了一种针对促存活蛋白BCL-XL的高效选择性小分子抑制剂。这项发现使开发针对BCL-XL的特定抗癌药物成为可能。BCL- XL属于一类有利于癌细胞存活的家族蛋白中的一种,其在肿瘤中通常过度表达。因为该蛋白家族很难作为小分子的标靶,所以只有一小部分药物能在临床发展应用 中有所表现。迄今为止,这些药物中没有一种能对特定的蛋白家族成员

PNAS:乙肝病毒靶标蛋白首次被发现

  近日,来自美国科罗拉多大学和中国厦门大学的两个研究小组在肝细胞中发现了乙型肝炎病毒(Hepatitis B virus, HBV)的两种主要靶标。这项发现可能导致人们开发出新的方法来治疗全世界当前大约感染这种病毒的4亿人中一些人所患的肝病。   科罗拉多大学教授Ding Xue说,科学家在过去三十多年一直都在寻找HBV的细胞靶标。HBV感染促进肝炎、肝硬化和肝癌产生,而且能够通过血液、体液、